PFE Today - Jul 12: Lung Cancer Trial Disappointment

カートのアイテムが多すぎます

ご購入は五十タイトルがカートに入っている場合のみです。

カートに追加できませんでした。

しばらく経ってから再度お試しください。

ウィッシュリストに追加できませんでした。

しばらく経ってから再度お試しください。

ほしい物リストの削除に失敗しました。

しばらく経ってから再度お試しください。

ポッドキャストのフォローに失敗しました

ポッドキャストのフォロー解除に失敗しました

PFE Today - Jul 12: Lung Cancer Trial Disappointment

無料で聴く

ポッドキャストの詳細を見る

Hey there! It’s Joey, your friendly neighborhood investor, here to break down what happened today with Pfizer. So, PFE had a red day, dropping about a third of a percent. Nothing too crazy, but still not great.

What went down? Well, it looks like folks are still feeling the sting from some disappointing news about a lung cancer trial. Yeah, that one stung. People were really hoping for a win there, but it didn’t pan out. On the flip side, there was some good news too—Pfizer got a thumbs up from the FDA for a new bladder cancer treatment. But the lung cancer news overshadowed that, and you know how it goes; bad news travels faster.

So why the drop? Investors are reacting to the lung cancer trial disappointment. It seems like that’s weighing heavy on everyone’s minds. Even though they had a win with the bladder cancer regimen, the market's mood was already set. When people see a setback like that, they tend to hit the sell button fast. It’s like a chain reaction, you know?

And just to throw a little extra info your way, Pfizer also had news about their Lyme disease vaccine showing some solid efficacy. But honestly, it feels like that news got lost in the shuffle today.

One thing worth knowing is that Pfizer’s got more in the pipeline, and they’re still pushing forward with their research. So, while today wasn’t a banner day, there's still stuff happening behind the scenes.

Alright, that’s a wrap for today’s recap! Hope that helped clear things up. Remember, I’m just here to share the info, not to give any financial advice. Catch you later!

まだレビューはありません